Sample collection
Sample collection is an intervention with 66 clinical trials. Currently 22 active trials ongoing. Historical success rate of 89.7%.
Success Metrics
Based on 26 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
86.7%
26 of 30 finished
13.3%
4 ended early
22
trials recruiting
66
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Exosome Cargo From Preeclampsia Patients
Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor
Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut
Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test
Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
Clinical Trials (66)
Exosome Cargo From Preeclampsia Patients
Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor
Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut
Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test
Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
Johns Hopkins Breast Cancer Program Longitudinal Repository
Longitudinal Oral Microbiome Sampling for BE
Oral Microbiome in Carotid Atherosclerosis
iSITE: Investigation of Somatic Alterations in Tumours of the Eye
Diabetes Reversal and the Subgingival Microbiota
Observational Study of Exposure to Environmental Toxicants Among Firefighters
Omics of Rituximab-resistance
A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients
Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario
Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer
Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer
Combinatorial Single Cell Strategies for a Crohn's Disease Gut Cell Atlas
SMS - Study of Somatic Mutations Using Genome Sequencing
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 66